Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial
Phase of Trial: Phase III
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Donafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 20 Mar 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
- 20 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
- 20 Mar 2017 Status changed from not yet recruiting to recruiting.